The investment fund Ysios Capital has closed a purchase agreement with the Swiss multinational CSL for a maximum price of 2.2 billion dollars (about 1.862 billion euros) for its start-up VarmX, the fund reported in a statement on Tuesday.

The Swiss-based biotechnology company ReproNovo, specializing in the development of reproductive health treatments, has closed a $65 million financing round, equivalent to approximately €57.4 million at the current exchange rate, and has announced the opening of a subsidiary in Barcelona. In fact, the Catalan asset manager Ysios Capital participated in the round, led by Jeito Capital. Other investors included AXA IM Alts, M Ventures, and Alsa Ventures.